1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. Polo-like Kinase (PLK)
  4. PLK4 Isoform

PLK4

 

PLK4 Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-18683
    Centrinone-B
    Inhibitor 98.71%
    Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM.
  • HY-132135
    (1E)-CFI-400437 dihydrochloride
    Inhibitor 98.89%
    (1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, VEGFR2/KDR/Flk-1 and FLT-3 with IC50s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity.
  • HY-12300
    Ocifisertib
    Inhibitor 98.45%
    CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
  • HY-128493
    PLK4-IN-4
    Inhibitor
    PLK4-IN-4 (compound 22) is a potent PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-4 has the potential for the research of cancer.
  • HY-115589
    YLT-11
    Inhibitor
    YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis.html" class="link-product" target="_blank">Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity.
  • HY-134775A
    PLK4-IN-3
    Inhibitor
    PLK4-IN-3 is a less active absolute stereochemistry of PLK4-IN-1. PLK4-IN-1 is a PLK4 inhibitor, with an IC50 of 0.65 μM.
  • HY-149912
    CZS-241
    Inhibitor
    CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC50=2.6 nM). CZS-241 inhibits TRKA with an IC50 value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines.